| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Rewards
Risk Analysis
No risks detected for 002020 from our risk checks.
Zhejiang Jingxin Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.57 |
| 52 Week High | CN¥15.25 |
| 52 Week Low | CN¥8.28 |
| Beta | 0.081 |
| 11 Month Change | 0.67% |
| 3 Month Change | -10.88% |
| 1 Year Change | -7.85% |
| 33 Year Change | 32.29% |
| 5 Year Change | 7.77% |
| Change since IPO | 680.55% |
Recent News & Updates
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Has Announced A Dividend Of CN¥0.30
May 21
Zhejiang Jingxin Pharmaceutical's (SZSE:002020) Problems Go Beyond Weak Profit
Apr 08Shareholder Returns
| 002020 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.0% | -3.1% | -0.8% |
| 1Y | -7.8% | -17.3% | -21.8% |
Return vs Industry: 002020 exceeded the CN Pharmaceuticals industry which returned -17.3% over the past year.
Return vs Market: 002020 exceeded the CN Market which returned -21.8% over the past year.
Price Volatility
| 002020 volatility | |
|---|---|
| 002020 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 002020 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002020's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,909 | Jin Zhiping | www.jingxinpharm.com |
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, Cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, sitagliptin, clopidogrel bisulfate, ticagrelor, rivaroxaban, apixaban, sisapele, esomeprazole, levetiracetam, bovaracetam, sertraline hydrochloride, pramipexole hydrochloride, rivastigmine bitartrate, memantine hydrochloride, and paliperidone. It also provides intermediates; and medical display products, such as diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, and ultrasonic medical displays.
Zhejiang Jingxin Pharmaceutical Co., Ltd. Fundamentals Summary
| 002020 fundamental statistics | |
|---|---|
| Market cap | CN¥9.10b |
| Earnings (TTM) | CN¥638.91m |
| Revenue (TTM) | CN¥4.10b |
14.2x
P/E Ratio2.2x
P/S RatioIs 002020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002020 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.10b |
| Cost of Revenue | CN¥2.02b |
| Gross Profit | CN¥2.08b |
| Other Expenses | CN¥1.44b |
| Earnings | CN¥638.91m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 15, 2024
| Earnings per share (EPS) | 0.74 |
| Gross Margin | 50.78% |
| Net Profit Margin | 15.59% |
| Debt/Equity Ratio | 5.8% |
How did 002020 perform over the long term?
See historical performance and comparison